Business Standard

Monday, January 06, 2025 | 06:10 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Alembic Pharma gains 5% on successful USFDA inspection of Panelav facility

The stock was up 5% at Rs 527 on the BSE in early morning trade after the company informed that the successful USFDA inspection at its API facility at Panelav with zero 483s.

Alembic Pharmaceuticals ups its US game plan, acquires Orit
Premium

Alembic Pharmaceuticals

SI Reporter Mumbai
Shares of Alembic Pharmaceuticals were up 5% at Rs 527 per share on the BSE in early morning trade after the company informed about the successful United States Food and Drug Administration (US FDA) inspection at its API facility at Panelav with zero 483s.

“The USFDA has conducted an inspection at Alembic Pharmaceuticals API Facility located at Panelav from 16th April, 2018 to 23rd April, 2018. This was a scheduled inspection and at the end of the inspection, there were zero 483s,” the pharmaceutical company said in a regulatory filing.

As per the USFDA, Form 483 notifies the

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in